NCT04258683 2023-08-29
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Canadian Myeloma Research Group
Phase 2 Withdrawn
Clinical Trials
8 trialsNCT03097796 2023-04-27
A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients
Pulmotect, Inc.
Phase 1 Withdrawn
NCT04282174 2022-09-27
2019-KOE-001
Baptist Health South Florida
Phase 2 Withdrawn
NCT04127721 2020-10-29
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02786485 2020-10-05
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Bellicum Pharmaceuticals
Phase 1 Withdrawn
NCT02155634 2018-04-10
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Celgene
Phase 3 Withdrawn
NCT00520325 2012-09-05
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT00594555 2008-10-31
A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia
University of Cincinnati
Phase 2 Withdrawn